Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
Appointed director

Aquestive Therapeutics, Inc. (AQST) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Other Events  Interactive Data
Docs: "Aquestive Therapeutics Provides Business Update"
10/02/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/11/2023 8-K Investor presentation
Docs: "of the Private Securities Litigation Reform Act of 1995. Words"
08/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/09/2023 4 BRAENDER LORI J (SVP, General Counsel) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 75,000 rights @ $0
08/09/2023 4 Barber Daniel (President and CEO) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 223,500 rights @ $0
08/09/2023 4 Marshall Ken W. (SVP, Chief Commercial Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 75,000 rights @ $0
08/09/2023 4 Boyd Peter E. (See Remark) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 50,000 rights @ $0
08/09/2023 4 Kraus Carl N (Chief Medical Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 150,000 shares @ $0
08/09/2023 4 Wargacki Stephen (SVP, Research & Development) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 67,500 rights @ $0
08/09/2023 4 TOTH A ERNEST JR (SVP, CFO) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 70,000 rights @ $0
08/09/2023 4 Schobel Alexander Mark (Chief Innovation/Tech Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 50,000 rights @ $0
08/09/2023 4 Jung Cassie (SVP, Operations) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 55,000 rights @ $0
08/07/2023 8-K Investor presentation, Quarterly results
Docs: "Exhibit 99.1 Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update"
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 8-K Quarterly results
07/27/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ Sublingual Film"
06/30/2023 3 Kraus Carl N (CHIEF MEDICAL OFFICER) has filed a Form 3 on Aquestive Therapeutics, Inc.
06/29/2023 8-K Investor presentation
Docs: "Aquestive Therapeutics Corporate Presentation",
"Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment"
05/31/2023 8-K Investor presentation
Docs: "Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm"
05/05/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/05/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/05/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/05/2023 4 BRAENDER LORI J (SVP, General Counsel) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 75,000 rights @ $0
05/05/2023 4 Barber Daniel (President and CEO) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 223,500 rights @ $0
05/05/2023 4 Marshall Ken W. (SVP, Chief Commercial Officer) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 75,000 rights @ $0
05/05/2023 4 Jung Cassie (SVP, Operations) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 55,000 rights @ $0
05/05/2023 4 Boyd Peter E. (See Remark) has filed a Form 4 on Aquestive Therapeutics, Inc.
Txns: Granted 50,000 rights @ $0
05/02/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/02/2023 8-K Quarterly results
05/02/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy